Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.

Cancer research - 15 Jul 2009

Talavera Ariel, Friemann Rosmarie, Gómez-Puerta Silvia, Martinez-Fleites Carlos, Garrido Greta, Rabasa Ailem, López-Requena Alejandro, Pupo Amaury, Johansen Rune F, Sánchez Oliberto, Krengel Ute, Moreno Ernesto

Abstract excerpt

Overexpression of the epidermal growth factor (EGF) receptor (EGFR) in cancer cells correlates with tumor malignancy and poor prognosis for cancer patients. For this reason, the EGFR has become one of the main targets of anticancer therapies. Structural data obtained in the last few years have revealed the molecular mechanism for ligand-induced EGFR dimerization and subsequent signal transduction, and also how...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Binding, Competitive

Share to Crystallography, X-Ray

Share to Immunoglobulin Fab Fragments

Share to Ligands

Share to Molecular Conformation

Share to Recombinant Fusion Proteins

Source

Identifiers

PMID: 19584289
DOI: 10.1158/0008-5472.CAN-08-4518

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.PMID 19584289Read ↗

Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologicsSemantic proximity Read ↗

Structures of the active HER2/HER3 receptor complex reveal dynamics at the dimerization interface induced by binding of a single ligandSemantic proximity Read ↗

Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface.Semantic proximity Read ↗

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.Semantic proximity Read ↗

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocksSemantic proximity Read ↗

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.Semantic proximity Read ↗

Role of N-glycosylation in EGFR ectodomain ligand binding.Semantic proximity Read ↗

Nanobodies targeting EGFR provide insight into conformations stabilized by glioblastoma mutations.Semantic proximity Read ↗

Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.Semantic proximity Read ↗

The EGF receptor Hokey-Cokey.Semantic proximity Read ↗

The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.Semantic proximity Read ↗

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.